Frontlight ResearchEarly access
TerminatedPhase 1/2
A Phase 1/2a, Single- and Multiple-dose Escalation Study of KRRO-110
Key facts
- Who runs it
- Korro Bio, Inc.
- Where
- Australia and New Zealand5 sites in 2 countriesChoose a country to see its sites
- Trial code
- Status
- Terminated
- Phase
- Phase 1/2
- People taking part
- 42 people enrolled
- Started
- 13 Jan 2025
- Ended
- 15 Dec 2025
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- KRRO-110
- Record updated
- 17 April 2026
- Why it stopped
- The study was terminated for business decision reasons.
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 23 criteriaShow less
Who can take part
- Part A SAD cohort Inclusion Criteria (Healthy Volunteers)
- Adult male or female participants, 18 to 65 years of age
- Documented PiMM genotype
- Participants who are willing to and able to provide signed written informed consent; PiZZ Genotype (Part A SAD and Part B MAD cohorts) Inclusion Criteria (PiZZ Genotype)
- Adult male or female participants 18 to 70 years of age (inclusive)
- Documented PiZZ genotype
- Baseline blood total AAT level < 11 µM/L
Who cannot take part
- Use of an experimental therapy except KRRO-110 within 6 months or 5 half-lives for the experimental therapy, whichever is greater
- Use of conventionally dosed AAT augmentation therapy within 5 half-lives
- History or current clinical evidence of hepatic disease
- Evidence of active infection
- History of medical condition(s), eg, advance cardiac disease, current or recent malignancy, organ transplantation, or other illness
- Serology result indicative of any exposure (past or active) to hepatitis C, hepatitis B, or human immunodeficiency virus (HIV)
- Respiratory or other acute illness within 8 weeks
- History of FEV1 < 35%
- History or current clinical evidence of advanced hepatic disease and/or pulmonary disease
- Serology result consistent with exposure to HIV, or serology consistent with active hepatitis B or hepatitis C infection
- Female participant of childbearing potential or male participant that is unable or unwilling to use an approved, reliable means of contraception
- Body mass index (BMI) > 32 or < 18.5 kg/m2
- Tobacco use of any kind within 6 months
- Female participant of childbearing potential or male participant that is unable or unwilling to use an approved, reliable means of contraception
- BMI > 32 or < 18.5 kg/m2 or weight > 90 kg
- Tobacco use of any kind within 6 months
This trial has no sites in United States.
It has sites in 2 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this first-in human (FIH) study is to assess the safety, tolerability, and pharmacokinetics (PK) of single and multiple doses of KRRO-110 in both healthy adult participants and in clinically stable patients with Alpha-1 antitrypsin deficiency (AATD).
The 2 groups in the trial
- Arm 1: KRRO-110 (Part A and Part B)Treatment being tested
KRRO-110 is an RNA editing oligonucleotide encapsulated in a lipid nanoparticle (LNP) administered by intravenous (IV) infusion as a single dose in Part A (SAD), multi-dose in Part B (MAD).
Treatment: KRRO-110
- Arm 2: Placebo (Part A only)Placebo, for comparison
Placebo, IV administration
Treatment: KRRO-110
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 1/2a, Single- and Multiple-dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KRRO 110 in Healthy Adult Volunteers and in Adult Participants With Alpha-1 Antitrypsin Deficiency (AATD) (REWRITE)
- Record updated
- 17 April 2026